July 29, 2022 MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report Read press release
July 28, 2022 MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000 Read press release
June 7, 2022 Videoconference and release of fiscal 2021-2022 financial results on June 14, 2022 Read press release
May 9, 2022 MedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer Read press release
May 3, 2022 MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM Read press release